{
    "clinical_study": {
        "@rank": "45472", 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if the vaccine, AIDSVAX B/E, will protect\n      intravenous drug users from becoming infected with HIV."
        }, 
        "brief_title": "Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand", 
        "completion_date": "August 2000", 
        "condition": [
            "HIV Infections", 
            "HIV Seronegativity"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Volunteers are immunized and followed for a minimum of 2 years. Any volunteer that becomes\n      infected with HIV-1 is followed every 4 months post infection for up to 36 months. Behavior\n      effects associated with study participation are assessed."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Volunteers may be eligible for this study if they:\n\n          -  Are 20 to 60 years old.\n\n          -  Are HIV-negative.\n\n          -  Have used intravenous drugs in the previous 12 months.\n\n          -  Are available and commit to 3 years of follow-up.\n\n          -  Have a Thai National ID or its equivalent such as government official ID or state\n             enterprise ID.\n\n          -  Are able to understand the study and pass a test showing they understand it, and give\n             written informed consent.\n\n        Exclusion Criteria\n\n        Volunteers will not be eligible for this study if they:\n\n          -  Have a serious disease or condition, or history of a serious disease or condition\n             such as lymphoma, that would interfere with the study.\n\n          -  Are HIV-positive.\n\n          -  Have ever received an experimental HIV-1 vaccine.\n\n          -  Have had or expect to have any treatments or medications that interfere with the\n             immune system (e.g., long-term use of systemic steroids, chemotherapy, or radiation).\n\n          -  Have received a vaccine or immunoglobulin within 2 weeks of receiving the first study\n             injection, or other vaccines within 4 weeks of the first study injection.\n\n          -  Have received immunoglobulins for a long time.\n\n          -  Have received non-licensed, research agents within 4 weeks of the first study\n             injection.\n\n          -  Expect to miss study visits or plan to move within 36 months.\n\n          -  Are pregnant or breast-feeding or plan to become pregnant during the 36-month study\n             period.\n\n          -  Are women who have sex with men and do not plan to use effective birth control."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": "2500", 
        "firstreceived_date": "October 2, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00006327", 
            "org_study_id": "VAX 003"
        }, 
        "intervention": {
            "intervention_name": "MN rgp120/HIV-1 and A244 rgp120/HIV-1", 
            "intervention_type": "Biological"
        }, 
        "keyword": [
            "Recombinant Proteins", 
            "HIV-1", 
            "AIDS Serodiagnosis", 
            "Substance Abuse, Intravenous", 
            "Enzyme-Linked Immunosorbent Assay", 
            "Blotting, Western", 
            "HIV Envelope Protein gp120", 
            "AIDSVAX"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Klongsan / Bangkok", 
                    "country": "Thailand"
                }, 
                "name": "Kachit Choopanya"
            }
        }, 
        "location_countries": {
            "country": "Thailand"
        }, 
        "official_title": "A Phase III Trial to Determine the Efficacy of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand", 
        "overall_official": {
            "last_name": "Kachit Choopanya", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00006327"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "VaxGen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 1999", 
        "study_design": "Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "June 2003"
    }, 
    "geocoordinates": {
        "Kachit Choopanya": "13.719 100.5"
    }
}